PCI Biotech has a project to document that PCI induces immunological mechanisms in cancer treatment, and to develop a treatment regime for optimal use of this mechanism.
Preclinical studies have been performed at University Hospital Zürich, Switzerland and at NTNU in Norway. Results from these studies show that under certain conditions, PCI can increase the effect of different antigens. Based on these promising results, the Board of Directors has decided to continue the preclinical program to develop and optimise a treatment regime for PCI used with vaccines. These preclinical studies will be performed at University Hospital Zurich in 2H 2012 and 1H 2013, with the aim to establish a protocol for a clinical study that can start in 2013.